| Title |
Exploring Different Strategies of Assessing the Economic Impact of Multiple Diabetes-Associated Complications and Their Interactions: A Large Claims-Based Study in Germany
|
|---|---|
| Published in |
PharmacoEconomics, August 2018
|
| DOI | 10.1007/s40273-018-0699-1 |
| Pubmed ID | |
| Authors |
Katharina Kähm, Michael Laxy, Udo Schneider, Rolf Holle |
| Abstract |
In the context of an aging population with increasing diabetes prevalence, people are living longer with diabetes, which leads to increased multimorbidity and economic burden. The primary aim was to explore different strategies that address the economic impact of multiple type 2 diabetes-related complications and their interactions. We used a generalized estimating equations approach based on nationwide statutory health insurance data from 316,220 patients with type 2 diabetes (baseline year 2012, 3 years of follow-up). We estimated annual total costs (in 2015 euros) for type 2 diabetes-related complications and, in addition, explored different strategies to assess diabetes-related multimorbidity: number of prevalent complications, co-occurrence of micro- and macrovascular complications, disease-disease interactions of prevalent complications, and interactions between prevalent/incident complications. The increased number of complications was significantly associated with higher total costs. Further assessment of interactions showed that macrovascular complications (e.g., chronic heart failure) and high-cost complications (e.g., end-stage renal disease, amputation) led to significant positive effects of interactions on costs, whereas early microvascular complications (e.g., retinopathy) caused negative interactions. The chronology of the onset of these complications turned out to have an additional impact on the interactions and their effect on total costs. Health economic diabetes models and evaluations of interventions in patients with diabetes-related complications should pay more attention to the economic effect of specific disease interactions. Politically, our findings support the development of more integrated diabetes care programs that take better account of multimorbidity. Further observational studies are needed to elucidate the shared pathogenic mechanisms of diabetes complications. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 48 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 6 | 13% |
| Researcher | 5 | 10% |
| Student > Bachelor | 4 | 8% |
| Other | 4 | 8% |
| Student > Ph. D. Student | 4 | 8% |
| Other | 5 | 10% |
| Unknown | 20 | 42% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 19% |
| Economics, Econometrics and Finance | 3 | 6% |
| Nursing and Health Professions | 2 | 4% |
| Psychology | 2 | 4% |
| Business, Management and Accounting | 1 | 2% |
| Other | 5 | 10% |
| Unknown | 26 | 54% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 September 2018.
All research outputs
#14,424,488
of 23,102,082 outputs
Outputs from PharmacoEconomics
#1,470
of 1,866 outputs
Outputs of similar age
#187,914
of 334,790 outputs
Outputs of similar age from PharmacoEconomics
#21
of 30 outputs
Altmetric has tracked 23,102,082 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,866 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one is in the 19th percentile – i.e., 19% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 334,790 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.